Abstract:Treatment of triple-negative breast cancer (TNBC) remains challenging. Deciphering the orchestration of metabolic pathways in regulating ferroptosis will provide new insights into TNBC therapeutic strategies. Here, we integrated the multiomics data of our large TNBC cohort (n = 465) to develop the ferroptosis atlas. We discovered that TNBCs had heterogeneous phenotypes in ferroptosis-related metabolites and metabolic pathways. The luminal androgen receptor (LAR) subtype of TNBC was characterized by the upregulation of oxidized phosphatidylethanolamines and glutathione metabolism (especially GPX4), which allowed the utilization of GPX4 inhibitors to induce ferroptosis. Furthermore, we verified that GPX4 inhibition not only induced tumor ferroptosis but also enhanced antitumor immunity. The combination of GPX4 inhibitors and anti-PD1 possessed greater therapeutic efficacy than monotherapy. Clinically, higher GPX4 expression correlated with lower cytolytic scores and worse prognosis in immunotherapy cohorts. Collectively, this study demonstrated the ferroptosis landscape of TNBC and revealed an innovative immunotherapy combination strategy for refractory LAR tumors.

What problem does this paper attempt to address?

The paper attempts to address the mechanisms of ferroptosis heterogeneity in triple-negative breast cancer (TNBC) and its implications for therapeutic strategies. Specifically, the researchers aim to discover new therapeutic targets and combination therapies by systematically analyzing the heterogeneity of ferroptosis in TNBC. ### Main Research Content: 1. **Systematic Analysis of Ferroptosis Heterogeneity**: - Researchers constructed a ferroptosis landscape for a large TNBC cohort (n=465) using multi-omics data (including transcriptomics, whole-exome sequencing, somatic copy number variations, and metabolomics data). - It was found that TNBC exhibits heterogeneity in ferroptosis-related metabolites and metabolic pathways. 2. **Ferroptosis Sensitivity of the LAR Subtype**: - The LAR subtype (androgen receptor-positive subtype) shows high sensitivity to ferroptosis inducers, particularly to GPX4 inhibitors. - Experiments confirmed that GPX4 inhibition not only induces tumor ferroptosis but also enhances anti-tumor immune responses. 3. **Combination Therapy of GPX4 Inhibitors and Immune Checkpoint Inhibitors**: - The study found that the combination of GPX4 inhibitors and anti-PD-1 antibodies has higher efficacy than monotherapy. - Clinical data indicate that high GPX4 expression is associated with lower cell lysis scores and poorer prognosis, especially in the immunotherapy cohort. ### Main Conclusions: - The study reveals the heterogeneity of ferroptosis in TNBC and identifies the high sensitivity of the LAR subtype to ferroptosis inducers. - A new therapeutic strategy is proposed, combining GPX4 inhibitors with immune checkpoint inhibitors, which may have better efficacy for patients with the LAR subtype of TNBC. ### Significance: - This research provides new insights into the precision treatment of TNBC, particularly for patients with the LAR subtype. - Targeting the ferroptosis pathway, combined with immunotherapy, holds the potential to improve treatment outcomes and survival rates for TNBC patients.

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy